Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: Systematic review and meta-analysis

CNS Drugs

Volumn 24, Issue 1, 2010, Pages 35-53

  Watanabe, Norio ^a   Omori, Ichiro M ^a   Nakagawa, Atsuo ^b   Cipriani, Andrea ^c   Barbui, Corrado ^c   McGuire, Hugh ^d   Churchill, Rachel ^d   Furukawa, Toshi A ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antidepressants, adverse reactions; Depression; Meta analysis; Mirtazapine, adverse reactions

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; DRUG DERIVATIVE; MIANSERIN;

ACUTE DISEASE; ADULT; ADVERSE OUTCOME; AGITATION; ANXIETY; ARTICLE; ASTHENIA; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSTHYMIA; FATIGUE; FLATULENCE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; INCREASED APPETITE; MENTAL DISEASE; META ANALYSIS; MOOD DISORDER; MULTIVARIATE ANALYSIS; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SALIVATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; UNIVARIATE ANALYSIS; VERTIGO; VOMITING; WEIGHT GAIN; XEROSTOMIA; COMPARATIVE STUDY; DRUG SURVEILLANCE PROGRAM; MAJOR DEPRESSION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; REVIEW;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; HUMANS; MIANSERIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS;

EID: 77649242513     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11319480-000000000-00000     Document Type: Article

References (44)

1. Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998 Nov 17; 159 (10): 1245-52 (Pubitemid 28554501)
2. Gregorian RS, Golden KA, Bahce A, et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002 Oct; 36 (10): 1577-89
3. De Boer T, Nefkens F, Van Helvoirt A. The alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 1994 Feb 21; 253 (1-2): R5-6
4. Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 2008; 69 (9): 1404-15
5. Gartlehner G, Hansen RA, Carey TS, et al. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int Clin Psychopharmacol 2005 Mar; 20 (2): 59-69 (Pubitemid 40354394)
6. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995 Nov; 56 (11): 519-25
7. Wade A, Crawford GM, Angus M, et al. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 2003 May; 18 (3): 133-41 (Pubitemid 36571056)
8. Hong CJ, Hu WH, Chen CC, et al. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003 Aug; 64 (8): 921-6
9. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000 Sep; 61 (9): 656-63
10. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder: Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999 Nov; 14 (6): 329-37 (Pubitemid 29531381)
11. Versiani M, Moreno R, Ramakers-van Moorsel CJ, et al. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005; 19 (2): 137-46 (Pubitemid 40321765)
12. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 2008; 22 (8): 843-8
13. Papanikolaou PN, Churchill R, Wahlbeck K, et al. Safety reporting in randomized trials of mental health interventions. Am J Psychiatry 2004 Sep; 161 (9): 1692-7 (Pubitemid 39201468)
14. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001 Jan 24-31; 285 (4): 437-43 (Pubitemid 32097262)
15. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001 Apr 18; 285 (15): 1987-91 (Pubitemid 32366951)
16. The Nordic Cochrane Centre. Review manager (RevMan) [computer program]. 5.0 ed. Copenhagen: The Cochrane Collaboration, 2008
17. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol 2002; 31 (1): 72-6 (Pubitemid 34284903)
18. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992; 116 (1): 78-84
19. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998 Nov 7; 317 (7168): 1309-12 (Pubitemid 28502420)
20. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses: sometimes informative, usually misleading. BMJ 1999 Jun 5; 318 (7197): 1548-51 (Pubitemid 29255803)
21. Schoemaker J, Gailledreau J, Hoyberg OJ. First, randomized, double-blind comparison of mirtazapine (15-45 mg) and fluvoxamine (50-150 mg) in the treatment of depression [abstract]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: 140
22. Thase ME, Kremer C, Rodrigues H. Mirtazapine versus sertraline after SSRI nonresponse. 52nd Institute on Psychiatric Services; 2000 Oct 25-29; Philadelphia (PA)
23. Debonnel G, Gobbi G, Turcotte J, et al. Effects of mirtazapine, paroxetine and their combination: a double-blind study in major depression [abstract]. Eur Neuropsychopharmacol 2000; 10 Suppl. 3: S252
24. Turan M, Askin R, Telcioglu M, et al. Mirtazapine versus amitriptyline in treatment of major depressive disorder. Eur Neuropsychopharmacol 2000; 10 Suppl. 3: S228
25. Marttila M, Jaaskelainen J, Jarvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995 Dec; 5 (4): 441-6
26. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995; 10 (4): 263-71
27. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*Dreport. Am J Psychiatry 2006 Jul; 163 (7): 1161-72 (Pubitemid 44464443)
28. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995 Mar; 10 (1): 3-9
29. Gardner DM, MacKinnon N, Langille DB, et al. A comparison of factors used by physicians and patients in the selection of antidepressant agents. Psychiatr Serv 2007 Jan; 58 (1): 34-40
30. Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998; 59 (3): 123-7 (Pubitemid 28150858)
31. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995 Dec; 10 Suppl. 4: 37-45
32. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001 Fall; 7 (3): 249-64 (Pubitemid 34016084)
33. Storosum JG, Elferink AJ, van Zwieten BJ, et al. Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies. Pharmacopsychiatry 2004 Jan; 37 (1): 32-6 (Pubitemid 38230737)
34. Brambilla P, Cipriani A, Hotopf M, et al. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry 2005 Mar; 38 (2): 69-77 (Pubitemid 40388786)
35. Greist J, McNamara RK, Mallinckrodt CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004 Sep; 26 (9): 1446-5
36. Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290 (7): 921-8
37. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 1167-70 (Pubitemid 36649048)
38. Perlis RH, Perlis CS, Wu Y, et al. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 2005; 162 (10): 1957-60 (Pubitemid 41428627)
39. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004 May 26; 291 (20): 2457-65 (Pubitemid 38669189)
40. Furukawa TA, Watanabe N, Omori IM, et al. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses.JAMA2007 Feb 7; 297 (5): 468-70
41. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-74
42. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007 Jun 28; 356 (26): 2684-92 (Pubitemid 47001036)
43. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007 Jun 28; 356 (26): 2675-83 (Pubitemid 47001035)
44. US FDA. FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications, 2007 May 2 [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01624.html [Accessed 2008 Jan 4]